Sachem Hill LLC Invests $531,000 in Stryker Corporation $SYK

Posted by Stanley Muller on Aug 20th, 2026

Sachem Hill LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 1,687 shares of the medical technology company’s stock, valued at approximately $531,000. Stryker accounts for approximately 0.1% of Sachem Hill LLC’s investment portfolio, making the stock its 19th largest position.

Several other hedge funds have also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. acquired a new stake in Stryker during the 2nd quarter worth $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the fourth quarter valued at about $26,000. Sankala Group LLC acquired a new stake in shares of Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the third quarter worth about $27,000. Finally, Atlas Capital Advisors Inc. purchased a new position in shares of Stryker in the fourth quarter worth about $27,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. Piper Sandler dropped their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Citigroup reissued a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Robert W. Baird set a $385.00 price target on Stryker in a research report on Friday, May 1st. Finally, Barclays cut their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

View Our Latest Stock Analysis on SYK

Stryker Trading Up 2.7%

Shares of SYK opened at $340.20 on Thursday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The firm has a market capitalization of $130.49 billion, a P/E ratio of 35.25, a P/E/G ratio of 2.11 and a beta of 0.76. The firm has a 50-day moving average price of $326.19 and a 200 day moving average price of $332.95. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 315,370 shares of company stock valued at $98,463,501. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.